NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NUROFree Report) in a report published on Friday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NeuroMetrix stock opened at $3.71 on Friday. NeuroMetrix has a fifty-two week low of $2.70 and a fifty-two week high of $8.30. The firm’s fifty day moving average price is $4.04 and its 200-day moving average price is $3.71. The stock has a market cap of $7.46 million, a P/E ratio of -0.59 and a beta of 2.16.

NeuroMetrix (NASDAQ:NUROGet Free Report) last released its quarterly earnings results on Wednesday, May 15th. The medical device company reported ($1.67) earnings per share for the quarter. NeuroMetrix had a negative net margin of 151.51% and a negative return on equity of 39.85%. The firm had revenue of $1.09 million for the quarter.

Institutional Investors Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Cerity Partners LLC purchased a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NUROFree Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned 2.80% of NeuroMetrix as of its most recent SEC filing. 19.40% of the stock is currently owned by institutional investors.

NeuroMetrix Company Profile

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.

Recommended Stories

Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.